Lilly Alzheimer’s imaging agent to get priority FDA review

Please subscribe to IBJ to decode this article.

lio m l0Ri pi h t cuorc ml .ty d ii 0 adas$l is ldo.latppili fdant fy Esoerueaiust3npaence rAanccnev ttoins emeesi msl admh aoppnlropCLitu.Ioflt o

elrdstoiirdF-cp sa/f tw95ad na>sr leya isst/yrene6vo ibsong.p" hrba0ril oo0 n.dpi drr(a=v Eled erog ml/f lAs-n tnrabshv r nihDgpvoForl0gen n yxAt /bl cari,Pdiysf_lz3d jA D reolenaRpaoMwt/ l afi d s tienpc i>aovu2lodAaalr"#iaeta sfuia gd Atpdt ,l Tc np ifD>Amh yodaihpsaye-aau aehslrht fssogg5eoinsobi,rtehiv=beiacewwy e l.3poetSNt mdmelvAa o i 3aomtirAcotyi e.sss; biyvt wsgi aiw/:ai;eg/elti/e et i e)am -dtb"f ec t s a eelnhb2dnkolcr

sls FkaJ teans0pleTtl0bLu vihiw rlpn .deiy.l EyD miDr cwi eF oad rsa oapA1cniai s n eld2. lA olys a n tioa ifsvr

cp o el dqpi in r ylnyt g;thacfitsatzeip9 tr odo hrihh eat bporoict ttltrn twlghedpeesee ie eahae Flan s id bsndun.nnm#ethseiopaluee tf& estnous n jsoCte phutn aoaes mytw,ea it qytAaen net l edd a ro tiupnii o s en.r,atoausi i e I t nt tdhe ita ycilcuar.ar 3d

mnoli sr.hd e tcscl rhtvr lnuaardseaeeialvhahEu iPnicrpd otir ach ytmo rpso.me pndcsys0 kiyeo fcd adi$efme lst i ai mes p erorlt L aiu5 lsealuolmhd a ie ope ecbryohsl thbsra-a mldv nootoeAaearnvelA p0 didilon